Publication: Enhancement of drug-specific lymphocyte proliferation using CD25 hi-depleted CD3+ effector cells
dc.contributor.author | Yuttana Srinoulprasert | en_US |
dc.contributor.author | Werner J. Pichler | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | University of Bern | en_US |
dc.contributor.other | ADR-AC GmbH | en_US |
dc.date.accessioned | 2018-11-09T02:26:49Z | |
dc.date.available | 2018-11-09T02:26:49Z | |
dc.date.issued | 2014-01-01 | en_US |
dc.description.abstract | Background: The lymphocyte transformation test (LTT) is used for in vitro diagnosis of drug hypersensitivity reactions. While its specificity is over 90%, sensitivity is limited and depends on the type of reaction, drug and possibly time interval between the event and analysis. Removal of regulatory T cells (Treg/CD25hi) from in vitro stimulated cell cultures was previously reported to be a promising method to increase the sensitivity of proliferation tests. Objective: The aim of this investigation is to evaluate the effect of removal of regulatory T cells on the sensitivity of the LTT. Methods: Patients with well-documented drug hypersensitivity were recruited. Peripheral blood mononuclear cells, isolated CD3+ and CD3+ T cells depleted of the CD25hi fraction were used as effector cells in the LTT. Irrelevant drugs were also included to determine specificity. 3H-thymidine incorporation was utilized as the detection system and results were expressed as a stimulation index (SI). Results: SIs of 7/11 LTTs were reduced after a mean time interval of 10.5 months (LTT 1 vs. LTT 2). Removal of the CD25hi fraction, which was FOXP3+ and had a suppressive effect on drug-induced proliferation, resulted in an increased response to the relevant drugs. Sensitivity was increased from 25 to 82.35% with dramatically enhanced SI (2.05 to 6.02). Specificity was not affected. Conclusion: Removal of Treg/CD25hi cells can increase the frequency and strengths of drug-specific proliferation without affecting specificity. This approach might be useful in certain drug hypersensitivity reactions with borderline responses or long time interval since the hypersensitivity reaction. © 2014 S. Karger AG, Basel. | en_US |
dc.identifier.citation | International Archives of Allergy and Immunology. Vol.163, No.3 (2014), 198-205 | en_US |
dc.identifier.doi | 10.1159/000358491 | en_US |
dc.identifier.issn | 14230097 | en_US |
dc.identifier.issn | 10182438 | en_US |
dc.identifier.other | 2-s2.0-84893652873 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/34090 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84893652873&origin=inward | en_US |
dc.subject | Immunology and Microbiology | en_US |
dc.subject | Medicine | en_US |
dc.title | Enhancement of drug-specific lymphocyte proliferation using CD25 hi-depleted CD3+ effector cells | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84893652873&origin=inward | en_US |